RPT193 is a small molecule CCR4 antagonist that blocks the recruitment of inflammatory immune cells, known as Th2 cells, which are clinically implicated in allergic inflammatory disorders. Our preclinical pharmacology and toxicology results for RPT193 show activity in clinically validated pathways in allergic inflammatory disease models to a degree we believe, if confirmed in clinical trials, could be competitive with currently marketed injectable biologics dosing and show a safety profile that suggests chronic dosing in humans should be well tolerated.
In August 2019, we initiated a Phase 1 single- and multiple-dose escalation clinical trial of RPT193 in 2019 in healthy volunteers, directly leading into a placebo-controlled Phase 1b cohort of patients with moderate to severe atopic dermatitis.
We are developing RPT193 for the treatment of a broad range of allergic inflammatory diseases, the first of which is atopic dermatitis (AD), a chronic, inflammatory skin disease characterized by skin barrier disruption and immune dysregulation. While there are existing injectable clinical products that are efficacious, as well as emerging oral drug candidates with seemingly comparable efficacy profiles, we believe there remains an unmet need for a safe, highly effective oral treatment. Our preclinical safety and efficacy results for RPT193, combined with the convenience of oral dosing, suggest a competitive profile compared to standard of care, including steroids and dupilumab, as well as clinical drug candidates, such as the JAK inhibitors, currently in development.